Navigation Links
CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer
Date:3/12/2009

offer commenced by Sturgeon Acquisition, Inc., Astellas US Holding, Inc. and Astellas Pharma Inc., the Company is filing with the Securities and Exchange Commission a Solicitation/Recommendation Statement on Schedule 14D-9. Stockholders of CV Therapeutics are advised to read CV Therapeutics' Schedule 14D-9 statement regarding the Astellas tender offer, because it contains important information. Stockholders may obtain a free copy of the statement at the SEC's website at www.sec.gov. Stockholders may also obtain, without charge, a copy of the statement from MacKenzie Partners, Inc., which is assisting CV Therapeutics, by calling 800-322-2885 toll free or by calling 212-929-5500 or by emailing cvtx@mackenziepartners.com.

This press release contains forward looking statements regarding the future financial and operating results of CV Therapeutics and other statements regarding its intentions, beliefs, expectations, plans, prospects or predictions for the future. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including: operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2008. CV Therapeutics disclaims any intent or obligation to
'/>"/>

SOURCE CV Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... 2014 The report "Data Center ... Security Equipment, WAN Optimization Appliances]: Global Advancements, Worldwide ... data center networking market into various segments with ... report also identifies the factors driving this market, ... along with the future roadmaps. , Browse 106 ...
(Date:10/25/2014)... The report “Adipic Acid Market ... - Global Trends & Forecast to 2019” report ... market drivers, opportunities, and trends in different regions. ... figures spread through 217 slides and in-depth TOC ... Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early buyers ...
(Date:10/25/2014)... 2014 BioProcess International (BPI), a ... 2014 BioProcess International Awards. The awards celebrate the ... and technology applications that will allow the industry ... global patient base. , Winners and finalists were ... very entertaining and exciting awards dinner and ceremony ...
(Date:10/25/2014)... October 24, 2014 DuPont Pioneer ... to more than double the acreage contracted for ... supplying its soybean crush facility in Salisbury, Md. ... program will target several markets including foodservice and ... good performance. , For the 2015 growing season, ...
Breaking Biology Technology:Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4
... , CINCINNATI, Sept. 16 Kendle (Nasdaq: ... the Company will participate in the upcoming UBS Global Life Sciences ... Hotel in New York City. , , (Logo: ... Kendle,s formal presentation will be given by Chairman and Chief ...
... ... other technologies for professional purposes and treatment decisions , ... New York, NY (PRWEB) September 16, 2009 -- ... biotech, and device corporate and product websites on a regular basis, according to pharmaceutical ...
... SOUTH SAN FRANCISCO, Calif., Sept. 16 Poniard ... focused on innovative oncology therapies, today announced that Jerry McMahon, ... overview at the 2009 UBS Global Life Sciences Conference on ... the Grand Hyatt Hotel in New York City. , ...
Cached Biology Technology:Kendle to Present at UBS Global Life Sciences Conference 2Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 2Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 3Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 4Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference 2
(Date:10/29/2014)... — Cambridge, MA and Hebei, China — BGI Tech ... quality sequencing of the Jujube genome. Jujube is the ... the Jujube genome is particularly difficult to sequence due ... It is the first time that a genome in ... has been recently published in Nature Communications ...
(Date:10/29/2014)... October 29, 2014 – Ghrelin is a hormone released ... intake. Alcohol is commonly viewed as a psychoactive substance ... a highly caloric food. , This knowledge, combined ... hypothesis that ghrelin has the potential to stimulate alcohol ... this in humans and found that, as they had ...
(Date:10/29/2014)... new study on a large cohort of kidney cancer ... of the disease -- and reveals an apparent link ... cancer, particularly in Romania. , The research, by an ... and Genome Quebec Innovation Centre in Montreal, underscores the ... acid. The compound, found in plants of the Aristolochia ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Ghrelin stimulates an appetite for drinking alcohol 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3
... for overcoming sleep deprivation. Sam Ridgway from the US Navy ... half of their brains to sleep while the other half ... able to remain continually vigilant for sounds for days on ... San Diego and Tel Aviv wonder whether the dolphins, unrelenting ...
... the first time, experts have compiled a comprehensive overview ... for the treatment of several cancers. , Personalizing Cancer ... of results of therapeutic regimens across a broad range ... Journal of Nuclear Medicine is a unique reference tool ...
... 2009 As people become more educated, studies have demonstrated ... calories but higher in nutrients. They also pay more. In ... Journal of the American Dietetic Association , researchers from ... costs of a sample of 164 adults in the Seattle, ...
Cached Biology News:Dolphins maintain round-the-clock visual vigilance 2Publication sets guidelines across cancer therapies: Ensuring the best in patient management 2People of higher socioeconomic status choose better diets -- but pay more per calorie 2
Pendrin (H-195)...
... thermostable, thermoactive designer enzyme that enables ... RNA PCR enzyme allows reverse transcription ... at elevated temperatures (65C), which helps ... template and results in highly stringent, ...
HLA-DRbeta (DA2)...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Biology Products: